相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
Shiro Komiya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2022)
Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease
Kota Kakeshita et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2022)
Prognostic impact of urine cyclic AMP levels in patients with chronic kidney disease
Kota Kakeshita et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2022)
Updates and Perspectives on Aquaporin-2 and Water Balance Disorders
Yumi Noda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Expression of aquaporin-2 in the collecting duct and responses to tolvaptan
Kota Kakeshita et al.
CEN CASE REPORTS (2021)
Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure - Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study -
Koichiro Kinugawa et al.
CIRCULATION JOURNAL (2019)
Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients
Takahiro Masuda et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure
Akihito Tanaka et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2019)
Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria
Koji Takagi et al.
HEART AND VESSELS (2018)
Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study
Takayuki Inomata et al.
CIRCULATION JOURNAL (2018)
Effects of Tolvaptan on Volume Overload in Patients with Heart Failure Meta-Analysis of Randomized Controlled Trials
Koichiro Kinugawa et al.
INTERNATIONAL HEART JOURNAL (2018)
Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
Mari Katsumata et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2017)
Urine Osmolarity Predicts the Body Weight-Reduction Response to Tolvaptan in Chronic Kidney Disease Patients: A Retrospective, Observational Study
Hirotsugu Iwatani et al.
NEPHRON (2015)
Increased Urine Aquaporin-2 Relative to Plasma Arginine Vasopressin Is a Novel Marker of Response to Tolvaptan in Patients With Decompensated Heart Failure
Teruhiko Imamura et al.
CIRCULATION JOURNAL (2014)
Effect of Tolvaptan in Patients With Chronic Kidney Disease Due to Diabetic Nephropathy With Heart Failure
Eiichi Sato et al.
INTERNATIONAL HEART JOURNAL (2014)
Novel Criteria of Urine Osmolality Effectively Predict Response to Tolvaptan in Decompensated Heart Failure Patients - Association Between Non-Responders and Chronic Kidney Disease
Teruhiko Imamura et al.
CIRCULATION JOURNAL (2013)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
分享论文
